CN105558244A - 一种辅助降血脂降血糖并提高免疫力的食品及其制备方法 - Google Patents
一种辅助降血脂降血糖并提高免疫力的食品及其制备方法 Download PDFInfo
- Publication number
- CN105558244A CN105558244A CN201510983222.4A CN201510983222A CN105558244A CN 105558244 A CN105558244 A CN 105558244A CN 201510983222 A CN201510983222 A CN 201510983222A CN 105558244 A CN105558244 A CN 105558244A
- Authority
- CN
- China
- Prior art keywords
- extract
- food
- parts
- plum
- immunity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 65
- 230000036039 immunity Effects 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 210000004369 blood Anatomy 0.000 title abstract description 44
- 239000008280 blood Substances 0.000 title abstract description 44
- 150000002632 lipids Chemical class 0.000 title abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 124
- 240000000588 Hericium erinaceus Species 0.000 claims abstract description 36
- 235000007328 Hericium erinaceus Nutrition 0.000 claims abstract description 36
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 241001165494 Rhodiola Species 0.000 claims abstract description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 31
- 240000004507 Abelmoschus esculentus Species 0.000 claims description 29
- 235000003934 Abelmoschus esculentus Nutrition 0.000 claims description 29
- 229940111793 eggplant extract Drugs 0.000 claims description 20
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 18
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 18
- 244000061458 Solanum melongena Species 0.000 claims description 17
- 235000002597 Solanum melongena Nutrition 0.000 claims description 17
- 241001105098 Angelica keiskei Species 0.000 claims description 15
- 241000209140 Triticum Species 0.000 claims description 15
- 235000021307 Triticum Nutrition 0.000 claims description 15
- 230000002402 anti-lipaemic effect Effects 0.000 claims description 15
- 244000163122 Curcuma domestica Species 0.000 claims description 14
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 14
- 235000003373 curcuma longa Nutrition 0.000 claims description 14
- 235000013976 turmeric Nutrition 0.000 claims description 14
- 229940055416 blueberry extract Drugs 0.000 claims description 13
- 235000019216 blueberry extract Nutrition 0.000 claims description 13
- 150000004676 glycans Chemical class 0.000 claims description 12
- 229920001282 polysaccharide Polymers 0.000 claims description 12
- 239000005017 polysaccharide Substances 0.000 claims description 12
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 11
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 10
- 238000004806 packaging method and process Methods 0.000 claims description 8
- 235000021110 pickles Nutrition 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 150000002596 lactones Chemical class 0.000 claims description 4
- 235000011888 snacks Nutrition 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 239000009405 Ashwagandha Substances 0.000 abstract 2
- 240000004482 Withania somnifera Species 0.000 abstract 2
- 235000001978 Withania somnifera Nutrition 0.000 abstract 2
- 229940069825 okra extract Drugs 0.000 abstract 2
- 235000021018 plums Nutrition 0.000 abstract 2
- DBRXOUCRJQVYJQ-CKNDUULBSA-N withaferin A Chemical compound C([C@@H]1[C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=C[C@H](O)[C@@]65O[C@@H]6C[C@H]4[C@@H]3CC2)C)C)C(C)=C(CO)C(=O)O1 DBRXOUCRJQVYJQ-CKNDUULBSA-N 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 48
- 206010012601 diabetes mellitus Diseases 0.000 description 27
- 230000000694 effects Effects 0.000 description 26
- 235000012000 cholesterol Nutrition 0.000 description 21
- 208000031226 Hyperlipidaemia Diseases 0.000 description 15
- 235000005911 diet Nutrition 0.000 description 11
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 230000036737 immune function Effects 0.000 description 8
- -1 chlorins compound Chemical class 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 206010016256 fatigue Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 4
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 4
- 235000012754 curcumin Nutrition 0.000 description 4
- 229940109262 curcumin Drugs 0.000 description 4
- 239000004148 curcumin Substances 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 150000002213 flavones Chemical class 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 150000001789 chalcones Chemical class 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000003345 hyperglycaemic effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 102000009433 Insulin Receptor Substrate Proteins Human genes 0.000 description 2
- 108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102000000536 PPAR gamma Human genes 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- 229930014669 anthocyanidin Natural products 0.000 description 2
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 2
- 235000008758 anthocyanidins Nutrition 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- MPCAJMNYNOGXPB-SLPGGIOYSA-N 1,5-anhydro-D-glucitol Chemical compound OC[C@H]1OC[C@H](O)[C@@H](O)[C@@H]1O MPCAJMNYNOGXPB-SLPGGIOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000035762 Disorder of lipid metabolism Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 101150026109 INSR gene Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CFLNHFUPWNRWJA-UHFFFAOYSA-N Obtusin Chemical compound O=C1C2=CC(C)=C(O)C(OC)=C2C(=O)C2=C1C=C(OC)C(OC)=C2O CFLNHFUPWNRWJA-UHFFFAOYSA-N 0.000 description 1
- OBBJQZSMXOJMCN-UHFFFAOYSA-N Obtusin Natural products COc1cc2C=CC(=O)Oc2c3OCC(Oc13)C(=C)C OBBJQZSMXOJMCN-UHFFFAOYSA-N 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000017343 Phosphatidylinositol kinases Human genes 0.000 description 1
- 108050005377 Phosphatidylinositol kinases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000042430 Rhodiola rosea Species 0.000 description 1
- 235000003713 Rhodiola rosea Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 229930182482 anthraquinone glycoside Natural products 0.000 description 1
- 229940098421 anthraquinone glycoside Drugs 0.000 description 1
- 150000008139 anthraquinone glycosides Chemical class 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 231100001028 renal lesion Toxicity 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/50—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by shape, structure or physical form, e.g. products with supported structure
- A23G3/54—Composite products, e.g. layered, coated, filled
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G2200/00—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents
- A23G2200/04—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents containing vitamins, antibiotics, other medicaments
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G2200/00—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents
- A23G2200/14—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents containing fruits, nuts, e.g. almonds, seeds, plants, plant extracts, essential oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G2220/00—Products with special structure
- A23G2220/20—Products with special structure with a composite structure, e.g. laminated products, coated products, microstructures, e.g. with encapsulated ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种辅助降血脂降血糖并提高免疫力的食品,由李子蜜饯和外包裹物组成,所述外包裹物包括非洲醉茄提取物、猴头菇提取物、秋葵提取物、红景天提取物,其特征在于:其由下述重量配比组成:李子蜜饯:40-60份;非洲醉茄提取物:5-13份;猴头菇提取物:5-13份;秋葵提取物:5-14份;红景天提取物:5-25份;另外,本发明还提供了该食品的制备方法。本发明提供一种可以作为零食的功能性原料复方组合物食品,解决了在同一产品中难以同时实现降低血糖、降血脂并提高免疫力的问题。
Description
技术领域
本发明属于保健食品技术领域,具体是涉及一种辅助降血脂降血糖并提高免疫力的食品及其制备方法。
背景技术
随着社会的发展,人们生活水平的不断提高,膳食结构及生活方式的变化,糖尿病和高脂血症的发病率日益增加,二者经常互为因果,合并发生。糖尿病患者由于胰岛素的生物调节作用发生障碍,常伴有脂质代谢的紊乱,出现甘油三酯水平升高、高密度脂蛋白水平降低、胆固醇水平升高为主要表现的高脂血症。糖尿病合并高血脂更容易导致脑中风、冠心病、肢体坏死、眼底病变、肾脏病变、神经病变等,这些糖尿病的远期并发症是造成糖尿病患者残疾或过早死亡的主要原因。同时,高脂饮食是2型糖尿病及胰岛素抵抗综合征发病的重要环境因素。因此,对于糖尿病合并高脂血症的患者,同时降低血糖和血脂,可以减少并发症的发生,提高患者生活质量,降低死亡率。另外,高血糖高血脂均可导致免疫功能发生紊乱,进一步加重病情发展。因此提高机体免疫功能是糖尿病和高脂血症的重要治疗原则。中国的传统食养,主张通过饮食调理,进行膳食养生,强身健体,并防治疾病。调整饮食结构,科学、健康的食养也是糖尿病、高脂血症防治不可忽视的重要手段,另外,选取成分适当的食品还可以对糖尿病、高脂血症起到有效的辅助治疗作用。
糖尿病的治疗包括饮食疗法和运动疗法,当这些疗法疗效不足时,再加上药物疗法。在饮食疗法中,建议患者避免过量饮食,坚持合理的热量摄取量。当或者肥胖时,指导其努力减至标准体重。作为饮食疗法所用的食品,公知的有国家已批准的特别用于糖尿病患者饮食的多样混合食品。但是,这些最多只是所谓的低热营养平衡食物,对糖尿病并没有实质上的疗效。
另外,医疗机构将这些疗法用于糖尿病患者,但并没有用于所谓的潜在糖尿病患者,而这些患者的数量远远超过糖尿病患者。因此,需要能有效预防或改善糖尿病的食品的组合物,例如:健康食品(健康专用食品和营养要求食品)或保健食品,或可以作为零食常用,携带方便,有医疗、保健作用的绿色食品。
发明内容
有鉴于此,本发明的目的在于提供一种可以作为零食的功能性原料复方组合物食品,解决了在同一产品中难以同时实现降低血糖、降血脂并提高免疫力的问题;另外还提供其制备方法,简单易行,成本低。
为达到上述目的,本发明提供如下技术方案:
一种辅助降血脂降血糖并提高免疫力的食品,以李子蜜饯为载体,采用药食同源或者可用于保健食品的植物作为有效成分,其中所述的药食同源或可用于保健食品的植物是由李子蜜饯和外包裹物组成,所述外包裹物包括非洲醉茄提取物、猴头菇提取物、秋葵提取物、红景天提取物,其特征在于:其由下述重量配比组成:李子蜜饯:40-60份;非洲醉茄提取物:5-13份;猴头菇提取物:5-13份;秋葵提取物:5-14份;红景天提取物:5-25份。
优选地:所述李子蜜饯中的含水率为20%-30%。
优选地:所述非洲醉茄提取物中的醉茄内酯含量为3%-8%。
优选地:所述猴头菇提取物中的猴头多糖含量为40%-60%。
优选地:所述秋葵提取物中的秋葵多糖含量为20%-40%,黄酮含量为2%-5%。
优选地:所述红景天提取物中的红景天苷及红景天苷元含量为3%-8%。
优选地:所述外包裹物还包括麦苗粉、姜黄提取物、蓝莓提取物、水苏糖、决明子提取物、藤黄果提取物、明日叶提取物,其中,麦苗粉:2.5-4.5份;姜黄提取物:1-3份;蓝莓提取物:2-4份;水苏糖:2-4份;决明子提取物:2.5-4.5份;藤黄果提取物:2-4;明日叶提取物:4-6份。
优选地:所述各组分的重量百分比为:李子蜜饯:50.6份;非洲醉茄提取物:6.4份;猴头菇提取物:6.4份;秋葵提取物:6.4份;红景天提取物:6.4份;麦苗粉:3.4份;姜黄提取物:1.9份;蓝莓提取物:3.2份;水苏糖:3.2份;决明子提取物:3.8份;藤黄果提取物:3.2;明日叶提取物:5.1份。
一种辅助降血脂降血糖并提高免疫力的食品的制备方法:
(1)先将非洲醉茄提取物、猴头菇提取物、秋葵提取物、红景天提取物,或麦苗粉、姜黄提取物、蓝莓提取物、水苏糖、决明子提取物、藤黄果提取物、明日叶提取物,或它们的混合物分别计量在混合搅拌设备中混合均匀,得外包裹物;
(2)将混合均匀的外包裹物投入烘焙机中进行烘烤,烘烤温度为65±5℃,烘烤时间12h;
(3)将李子用7%的食盐水渍至转黄后,将李子捞出,用清水把李子进行漂洗,漂洗时每隔2小时换水1次,共换水3次,然后将浸渍好的李子放入5%的糖水溶液中腌制36小时,即得所需李子蜜饯;
(4)先将计量好的步骤(3)中的李子蜜饯倒入混合机中搅拌混合5min-10min,再把计量好的步骤(2)中处理好的外包裹物均匀洒在蜜饯表面,继续搅拌至外包裹物均匀地包裹在李子蜜饯的表面,获得食品;
(5)把包装袋,步骤(4)所得食品在强度为30W的紫外线下照射30分钟,消毒杀菌,然后及时包装,入库。
本发明的工艺流程图如图1所示:
本发明的有益效果在于:
(1)本食品取材天然、味道鲜美、作为一种零食常用,不仅可解馋食,亦可有医疗、保健作用,且携带方便,是一款可以同时实现降低血糖、降血脂并提高免疫力的绿色保健食品。
(2)本发明采用非洲醉茄提取物、猴头菇提取物、秋葵提取物、红景天提取物作为外包裹物的主要成分,配伍合理,功效明显。非洲醉茄提取物—醉茄素类化合物作为羟甲基戊二酰辅酶A还原酶抑制剂(HMG-CoA还原酶抑制剂),可抑制胆固醇合成,同时提高高密度脂蛋白(HDL),运载周围组织中的胆固醇,再转化为胆汁酸或直接通过胆汁从肠道排,从而促进胆固醇的代谢;非洲醉茄提取物—醉茄素类化合物可改善受损的胰岛β细胞的功能,降低血糖;醉茄提取物—醉茄素类化合物增强诱生型一氧化氮合酶(iNOS)活性,促进小鼠巨噬细胞中NO的产生,促进Th1细胞功能,提高机体的非特异性免疫功能。猴头菇提取物—猴头菇多糖具有降血脂、降血糖的作用;其增强小鼠腹腔巨噬细胞的吞噬能力,对脾脏淋巴细胞有显著的促进增殖作用,对非特异性和特异性免疫功能都有提高作用;同时可改善受损的胰岛β细胞的功能,降低血糖。秋葵提取物通过调节过氧化物增殖激活受体(PPARγ),调节血脂和血糖相互之间转化的动态平衡,秋葵通过调节PPARγ,改善胰岛素抵抗。红景天提取物对细胞免疫、体液免疫及非特异性免疫均有增强作用。非洲醉茄提取物可降血脂、降血糖及提高免疫力,猴头菇提取物可降血糖、降血脂及提高免疫力,秋葵提取物可降血脂、降血糖,红景天提取物可提高免疫力,主要成分的用量均小于现有产品的最小有效量,而主要成分配伍后又可降脂、降糖并提高机体免疫力,同时,避免了某单独成分大量应用所致副反应的发生,保证了本发明产品的安全性。
(3)本发明采用非洲醉茄提取物、猴头菇提取物、秋葵提取物、红景天提取物作为外包裹物的主要成分,配以麦苗粉、姜黄提取物、蓝莓提取物、水苏糖、决明子提取物、藤黄果提取物、明日叶提取物,复配后降血糖、降血脂及提高免疫力效果更好。其中麦苗粉富含叶绿素、胡萝卜素、蛋白质、必需氨基酸、维他命、活性酵素、矿物质、纤维素等天然营养素,除了降低血糖外,还可降低甘油三脂和胆固醇含量,提高高密度脂蛋白含量,增强机体免疫力。姜黄提取物姜黄素减少低密度脂蛋白(LDL)的氧化作用和异常血管平滑肌增生,从而减轻动脉粥样硬化,降低甘油三酯和胆固醇。藤黄果和蓝莓中黄酮类化合物可降低极低密度脂蛋白,提高HDL,降低胆固醇和甘油三酯。水苏糖抑制胆固醇合成。决明子中蒽醌类成份减少肠道对胆固醇的吸收,并增加其排泄;决明子提取物在降低血糖的同时,通过清除自由基,抑制过氧化,改善晶状体内的过氧化状态,抑制肾纤维化等并发症;决明子提取物还能提高小鼠外周血白细胞及T淋巴细胞数,刺激T淋巴细胞转化,增加机体细胞免疫功能,增强巨噬细胞的吞噬功能,提高非特异性免疫。明日叶查尔酮类促进脂肪细胞对葡萄糖的摄取,增加肝脏和肌肉细胞摄取2-脱氧葡萄糖的能力,降低空腹血糖和胰岛素水平,同时上调糖尿病模型小鼠肝细胞磷脂酰肌醇激酶PI3K、肝细胞胰岛素受体(InsR)和胰岛素受体底物-2(IRS-2)的mRNA表达,减轻胰岛素抵抗。本发明的组合物作用协同,机理互补,可全面、系统辅助降低血糖、降低血脂,对血糖、血脂偏高者具有显著的防治作用;并辅助有效改善糖尿病、高脂血症患者并发症。同时,本发明各组分通过不同路径,提高机体免疫力,可辅助有效纠正糖尿病、高脂血症患者免疫功能紊乱,减少并发症。
附图说明
图1为本发明辅助降血脂降血糖并提高免疫力的食品的制备方法的工艺流程图。
具体实施方式
下面将结合具体实施例,对本发明的优选实施例进行详细的描述。如无特别说明,其中的百分比均为质量百分比。
本发明提供一种辅助降血脂降血糖并提高免疫力的食品,是一种向糖尿病并发高血脂症患者食用,该食品外包裹物采用黄酮类、多糖类、苷元、内酯及蒽醌类协同组合,达到降血脂、降血糖并提高免疫力的目的,从而辅助有效改善糖尿病、高脂血症患者并发症,且同食品中各种单独的活性物质相关的药效作用相比,该组合物具有更强的降血糖、降血脂及提高免疫力的作用。
本实施例中所用的李子蜜饯的含水率为20%-30%,其富含多种氨基酸、钙、磷、铁、胡萝卜素、维生素B1、维生素B2、烟酸、维生素C等,是配方的良好载体。
本实施例中所用的原材料除蜜饯李子外均为市购产品,其中,
非洲醉茄提取物购自西安瑞林,其醉茄内酯含量为3%-8%,其主要活性成分为醉茄素类化合物,给高胆固醇血症大鼠喂饲醉茄根粉后,发现其血浆中总脂、胆固醇、甘油三醋以及脂质过氧化水平大幅下降,同时HDL-C和HMG-CoA还原酶活性明显升高。在链脉佐菌素诱导的糖尿病大鼠模型实验中,给大鼠喂饲醉茄果实水提物,7周后能显著降低血糖、总胆固醇、血清和肝脏脂质过氧化物水平。醉茄根粉同样可以改善临床糖尿病患者脂质代谢。同时,醉茄增强诱生型一氧化氮合酶(iNOS)活性,促进小鼠巨噬细胞中NO的产生,促进Th1细胞功能,提高机体的免疫功能。
猴头菇提取物购自西安瑞林,其猴头菇多糖为40%-60%,其主要活性成分是多糖类物质,可以降血糖、降血脂,同时增强小鼠腹腔巨噬细胞的吞噬能力,对脾脏淋巴细胞有显著的促进增殖作用,具有显著的免疫增强作用。
秋葵提取物购自西安瑞林,其秋葵多糖的含量为20%-40%,黄酮含量为2%-5%,其富含有维生素A、胡萝卜素,以及维生素C、E及黄酮类,具有显著的降血脂、降血糖及抗疲劳功效。
红景天提取物购自西安瑞林,其红景天苷和红景天苷元含量为3%-8%,其主要成份为红景天苷和红景天苷元,具有增强免疫功能和抗疲劳功能。
麦苗粉购自兴化联富,其由优质鲜嫩麦苗烘干研磨成200目的细粉,且富含叶绿素、胡萝卜素、蛋白质、必需氨基酸、维他命、活性酵素、矿物质、纤维素等天然营养素,除了降低血糖外,还可降低甘油三脂和胆固醇含量,提高高密度脂蛋白含量,增强机体免疫力。
姜黄提取物购自兴化联富,其姜黄素的含量为95%,其主要成分为姜黄素、去甲氧基姜黄素、双去甲氧基姜黄素,姜黄素具有降低血浆总胆固醇、β-脂蛋白、甘油三酯和肝胆固醇,纠正α-和β-脂蛋白比例失调的作用,对血管有营养作用。
蓝莓提取物购自陕西柏威,其为深紫红色或紫色精细粉末,其中花青素(甙)25%、欧洲越橘花青素(甙)含量为20%,含量为20%,其果胶含量很高,能有效降低胆固醇,防止动脉粥样硬化,促进心血管健康。
水苏糖购自陕西柏威,有效含量不低于99%,其为功能性低聚糖,对肠道双歧杆菌、乳酸菌等益生菌有高选择性增殖效果,抑制胆固醇的合成,具有显著降脂作用,并对血糖没有影响。
决明子提取物购自西安瑞盈生物,其大黄素蒽醌酮和决明素含量为3.3%,所述决明子提取物的蛋白质、蒽醌苷皆可降低高脂血症大鼠的总胆固醇、三酰甘油和低密度脂蛋白胆固醇。另决明子可提高机体细胞免疫功能。
藤黄果提取物购自陕西柏威,其藤黄果素含量为60%,其富含黄酮类成分,可减缓脂肪形成,促进脂肪降解,具有显著降脂作用。
明日叶提取物购自陕西柏威,其查尔酮类化合物含量为10%,其查尔酮类化合物可通过调节细胞因子表达、调节细胞分化、促进细胞对葡萄糖摄取、调节胰岛素受体相关基因表达、抑制胰岛细胞凋亡等改善血糖。明日叶可升高高密度脂蛋白含量,降低肝脏胆固醇的重量。
实施例1:
李子蜜饯的制备:将李子用7%的食盐水渍至转黄后,将李子捞出,用清水把李子进行漂洗,漂洗时每隔2小时换水1次,共换水3次,然后将浸渍好的李子放入5%的糖水溶液中腌制36小时,即得所需李子蜜饯。
按照配方要求,将5份非洲醉茄提取物、5份猴头菇提取物、14份秋葵提取物、25份红景天提取物分别加入混合搅拌设备,开动搅拌混合均匀,得外包裹物;将混合均匀的外包裹物投入温度为65±5℃,烘烤12h;然后把制备好的51份李子蜜饯倒入混合机中搅拌混合5min-10min,再把处理好的49份外包裹物均匀洒在李子蜜饯表面,继续搅拌至外包裹物均匀地包裹在李子蜜饯的表面,即得食品;最后把包装袋,食品在强度为30W的紫外线下照射30分钟,消毒杀菌后,及时包装,入库。
实施例2:
李子蜜饯的制备:将李子用7%的食盐水渍至转黄为后,将李子捞出,用清水把李子进行漂洗,漂洗时每隔2小时换水1次,共换水3次,然后将浸渍好的李子放入5%的糖水溶液中腌制36小时,即得所需李子蜜饯。
按照配方要求,将13份非洲醉茄提取物、13份猴头菇提取物、10份秋葵提取物、5份红景天提取物分别加入混合搅拌设备,开动搅拌混合均匀,得外包裹物;将混合均匀的外包裹物投入温度为65±5℃,烘烤12h;然后把制备好的59份李子蜜饯倒入混合机中搅拌混合5min-10min,再把处理好的41份外包裹物均匀洒在李子蜜饯表面,继续搅拌至外包裹物均匀地包裹在李子蜜饯的表面,即得食品;最后把包装袋,食品在强度为30W的紫外线下照射30分钟,消毒杀菌后,及时包装,入库。
实施例3:
李子蜜饯的制备:将李子用7%的食盐水渍至转黄为后,将李子捞出,用清水把李子进行漂洗,漂洗时每隔2小时换水1次,共换水3次,然后将浸渍好的李子放入5%的糖水溶液中腌制36小时,即得所需李子蜜饯。
按照配方要求,将13份非洲醉茄提取物、10份猴头菇提取物、14份秋葵提取物、18份红景天提取物分别加入混合搅拌设备,开动搅拌混合均匀,得外包裹物;将混合均匀的外包裹物投入温度为65±5℃,烘烤12h;然后把制备好的45份李子蜜饯倒入混合机中搅拌混合5min-10min,再把处理好的55份外包裹物均匀洒在李子蜜饯表面,继续搅拌至外包裹物均匀地包裹在李子蜜饯的表面,即得食品;最后把包装袋,食品在强度为30W的紫外线下照射30分钟,消毒杀菌后,及时包装,入库。
实施例4:
李子蜜饯的制备:将李子用7%的食盐水渍至转黄为后,将李子捞出,用清水把李子进行漂洗,漂洗时每隔2小时换水1次,共换水3次,然后将浸渍好的李子放入5%的糖水溶液中腌制36小时,即得所需李子蜜饯。
按照配方要求,将份8非洲醉茄提取物、8份猴头菇提取物、8份秋葵提取物、8份红景天提取物、2.5份麦苗粉、1份姜黄提取物、2份蓝莓提取物、2份水苏糖、2.5份决明子提取物、2份藤黄果提取物、4份明日叶提取物,分别加入混合搅拌设备,开动搅拌混合均匀,得外包裹物;将混合均匀的外包裹物投入温度为65±5℃,烘烤12h;然后把制备好的52份李子蜜饯倒入混合机中搅拌混合5min-10min,再把处理好的48份外包裹物均匀洒在李子蜜饯表面,继续搅拌至外包裹物均匀地包裹在李子蜜饯的表面,即得食品;最后把包装袋,食品在强度为30W的紫外线下照射30分钟,消毒杀菌后,及时包装,入库。
实施例5:
李子蜜饯的制备:将李子用7%的食盐水渍至转黄为后,将李子捞出,用清水把李子进行漂洗,漂洗时每隔2小时换水1次,共换水3次,然后将浸渍好的李子放入5%的糖水溶液中腌制36小时,即得所需李子蜜饯。
按照配方要求,将份6.4非洲醉茄提取物、6.4份猴头菇提取物、6.4份秋葵提取物、6.4份红景天提取物、3.4份麦苗粉、1.9份姜黄提取物、3.2份蓝莓提取物、3.2份水苏糖、3.8份决明子提取物、3.2份藤黄果提取物、5.1份明日叶提取物,分别加入混合搅拌设备,开动搅拌混合均匀,得外包裹物;将混合均匀的外包裹物投入温度为65±5℃,烘烤12h;然后把制备好的50.6份李子蜜饯倒入混合机中搅拌混合5min-10min,再把处理好的49.4份外包裹物均匀洒在李子蜜饯表面,继续搅拌至外包裹物均匀地包裹在李子蜜饯的表面,即得食品;最后把包装袋,食品在强度为30W的紫外线下照射30分钟,消毒杀菌后,及时包装,入库。
实施例6:
李子蜜饯的制备:将李子用7%的食盐水渍至转黄为后,将李子捞出,用清水把李子进行漂洗,漂洗时每隔2小时换水1次,共换水3次,最后糖和李子放置到容器内腌制36小时,即得所需李子蜜饯。
按照配方要求,将份10非洲醉茄提取物、5份猴头菇提取物、5份秋葵提取物、10份红景天提取物、4.5份麦苗粉、3份姜黄提取物、4份蓝莓提取物、4份水苏糖、4.5份决明子提取物、4份藤黄果提取物、6份明日叶提取物,分别加入混合搅拌设备,开动搅拌混合均匀,得外包裹物;将混合均匀的外包裹物投入温度为65±5℃,烘烤12h;然后把制备好的40份李子蜜饯倒入混合机中搅拌混合5min-10min,再把处理好的60份外包裹物均匀洒在李子蜜饯表面,继续搅拌至外包裹物均匀地包裹在李子蜜饯的表面,即得食品;最后把包装袋,食品在强度为30W的紫外线下照射30分钟,消毒杀菌后,及时包装,入库。
通过以下实验数据可以验证本发明中主要成分的协同增效效果:
按照文献,本发明主要成分非洲醉茄提取物在动物(大鼠)实验中,抑制胆固醇合成,降低血糖的有效剂量为50-100mg/kg/d。根据体表面积折算方法,大鼠的等效剂量相当于人的6.3倍,按照以上方法,非洲醉茄在人的等效用量(按照60kg计算)为315-630mg/d。本发明中,单个李子的重量一般在1200mg,单个李子载体非洲醉茄提取物的质量比为5-13,即为60-120mg,按照每日服用2个(最大剂量)计算,每日服用量为120-312mg,小于等效剂量。因此,非洲醉茄提取物在该剂量下单独应用,不能发挥抑制胆固醇合成,降血糖的作用。本发明中,猴头菇提取物的有效成份为猴头菇多糖,以市场现售的猴头菇提取物服用剂量为例,其猴头菇多糖含量为50mg/粒,每日2次,每次2-3粒。每日服用猴头菇多糖的量为200-300mg。本发明中猴头菇提取物中猴头菇多糖的含量为40%-60%,单个李子载体猴头菇提取物所占质量比为5-13,即用量为100mg,猴头菇多糖的含量为24-93.6mg。按照每日服用2个(最大剂量)计算,每日服用量为48mg-187.2mg,小于目前现有产品的有效剂量。因此,猴头菇提取物在该剂量下单独应用时,不能发挥降糖降脂及提高免疫力等功效。本发明中,秋葵提取物的主要成分为秋葵多糖和黄酮。目前市售的秋葵提取物服用剂量为350mg/d。本发明中,单个李子载体秋葵提取物所占质量比为5-14,即其用量为120mg-336mg,小于目前市场产品的有效剂量,单独应用时,不能发挥降脂降糖等功效。本发明中,红景天提取物可提高机体免疫力,目前市售四川宝兴制药有限公司生产的红景天胶囊,250mg/粒,2粒/次,2次/日,每日的服用剂量达1000mg。本发明中,单个李子红景天提取物所占质量比为5-25,即其用量为120mg-216mg,单独应用时,小于目前现有产品的有效剂量,不能发挥提高机体免疫力的作用。
本发明中主要成分的用量均小于市售产品的最小有效量,而主要成分配伍后又可降脂、降糖并提高机体免疫力,同时,避免了某单独成分大量应用所致副反应的发生,既协同增效,又有力保证了本发明产品的安全性。
为验证本配方主要成分和辅助成分的协同增效作用,设计如下实验:试验人群为高脂血症合并糖尿病患者,将实验人分为配方(主要成分加辅助成分)应用组、主要成分应用组和辅助成分应用组,每组20人,2粒/人/天,共服用3个月,结果显示如下表所示:
单纯使用辅助成分配合的食品,则血糖血脂下降不明显,症状缓解不显著;单纯使用主要成分配合的食品,则胆固醇、甘油三脂及血糖含量均有所下降,且疲乏无力等症状有一定的改善;采用主要成分与辅助成分配合的食品,则胆固醇、甘油三脂及血糖含量均有比较大幅度的下降,且疲乏无力症状显著减轻;由以上数据提示可知,配方中主要成分和辅助成分在降糖降脂及提高免疫力方面具有协同增效的作用。
临床使用效果:
为了表明本发明的食品对高血脂、高血糖患者的治疗效果,本发明采用患者自愿原则对其进行跟踪采访和检测,在观察的过程中,并对上述患者进行记录其病史、病情、年龄及疗效的工作。
本发明食品的食用方法为:
(1)每日两次,餐后或随餐服用。
(2)使用以30天为一疗程,连续使用3个月效果更佳。
(3)本发明使用的李子内有核,幼儿禁用。
治疗效果的判断标准为:
治愈:症状、体征全部消失,化验指标均在正常范围。
好转:自觉症状如胸闷、腹胀、倦怠乏力、头晕头痛等基本消失,化验血糖、血脂接近正常值。
无效:症状、体征、化验指标无明显改善。
食疗效果:本发明的食品经对200名高血脂、高血糖患者进行食疗,具体效果如下:
(1)采用自愿原则,本发明的食品经对100名食用该配方食品的高血脂人员进行跟踪采访与检测,结果发现:食用60天,80%的人不同程度的腰围降低,腰围降低范围5cm-10cm不等,轻度脂肪肝消失;60%人血生化检测,甘油三酯降至2.26mmol/l以下,胆固醇降至6.0mnol/l以下。
(2)采用自愿原则,本发明的食品经过100名食用该配方食品的高血糖患者(7.0-10mmol/l不等)进行跟踪采访和检测,结果发现:食用该配方30天后,90%的人空腹血糖指标有明显降低,降低率为5-20%不等。其中25人的空腹血糖水平在不服用降糖药后也回归6.0mmol/l,且观察1周没有反复,维持正常值。
典型病例:
病例1:患者张某,男,48岁,患高脂血症3年,轻度脂肪肝,出现心慌、容易疲乏等症状,胆固醇6.4mnol/l。单纯服用本发明中药六个月,配合饮食控制,疲乏无力等症状消失,查体无脂肪肝,胆固醇降至5.34mnol/l。
病例2:患者王某某,男,50岁,患糖尿病2年,体胖,自觉疲乏无力,多饮,多尿,口渴,空腹血糖7.8mmol/l.单纯服用本发明6个月后,配合饮食控制,口渴、多饮、乏力等症状明显减轻,空腹血糖降至6.1mmol/l。
病例3:患者高某,男,53岁,患糖尿病合并高脂血症5年,轻度脂肪肝。体胖,自觉胸闷,口渴,疲乏无力。空腹血糖8.5mmol/l,甘油三酯2.5mmol/l,胆固醇6.5mmol/l。单纯服用本发明6个月,配合饮食控制,胸闷等症状消失,空腹血糖降至6.5mmol/l。甘油三酯降至1.7mmol/l,胆固醇降至5.34mmol/l。
最后说明的是,以上优选实施例仅用以说明本发明的技术方案而非限制,尽管通过上述优选实施例已经对本发明进行了详细的描述,但本领域技术人员应当理解,可以在形式上和细节上对其作出各种各样的改变,而不偏离本发明权利要求书所限定的范围。
Claims (9)
1.一种辅助降血脂降血糖并提高免疫力的食品,由李子蜜饯和外包裹物组成,所述外包裹物包括非洲醉茄提取物、猴头菇提取物、秋葵提取物、红景天提取物,其特征在于:所述食品由下述重量配比组成:李子蜜饯:40-60份;非洲醉茄提取物:5-13份;猴头菇提取物:5-13份;秋葵提取物:5-14份;红景天提取物:5-25份。
2.根据权利要求1所述的辅助降血脂降血糖并提高免疫力的食品,其特征在于:所述李子蜜饯中的含水率为20%-30%。
3.根据权利要求1所述的辅助降血脂降血糖并提高免疫力的食品,其特征在于:所述非洲醉茄提取物中的醉茄内酯含量为3%-8%。
4.根据权利要求1所述的辅助降血脂降血糖并提高免疫力的食品,其特征在于:所述猴头菇提取物中的猴头多糖含量为40%-60%。
5.根据权利要求1所述的辅助降血脂降血糖并提高免疫力的食品,其特征在于:所述秋葵提取物中的秋葵多糖含量为20%-40%。
6.根据权利要求1所述的辅助降血脂降血糖并提高免疫力的食品,其特征在于:所述红景天提取物中的红景天苷及红景天苷元含量为3%-8%。
7.根据权利要求1所述的辅助降血脂降血糖并提高免疫力的食品,其特征在于:所述外包裹物还包括麦苗粉、姜黄提取物、蓝莓提取物、水苏糖、决明子提取物、藤黄果提取物、明日叶提取物,其中,麦苗粉:2.5-4.5份;姜黄提取物:1-3份;蓝莓提取物:2-4份;水苏糖:2-4份;决明子提取物:2.5-4.5份;藤黄果提取物:2-4;明日叶提取物:4-6份。
8.根据权利要求7所述的辅助降血脂降血糖并提高免疫力的食品,其特征在于:所述各组分的重量百分比为:李子蜜饯:50.6份;非洲醉茄提取物:6.4份;猴头菇提取物:6.4份;秋葵提取物:6.4份;红景天提取物:6.4份;麦苗粉:3.4份;姜黄提取物:1.9份;蓝莓提取物:3.2份;水苏糖:3.2份;决明子提取物:3.8份;藤黄果提取物:3.2;明日叶提取物:5.1份。
9.一种用于制备如权利要求1-8中任一项所述的辅助降血脂降血糖并提高免疫力的食品的方法,其包括以下步骤:
(1)先将非洲醉茄提取物、猴头菇提取物、秋葵提取物、红景天提取物、或麦苗粉、姜黄提取物、蓝莓提取物、水苏糖、决明子提取物、藤黄果提取物、明日叶提取物,或它们的混合物分别计量在混合搅拌设备中混合均匀,得外包裹物;
(2)将混合均匀的外包裹物投入烘焙机中进行烘烤,烘烤温度为65±5℃,烘烤时间12h。
(3)将李子用7%的食盐水渍至转黄后,将李子捞出,用清水把李子进行漂洗,漂洗时每隔2小时换水1次,共换水3次,然后将浸渍好的李子放入5%的糖水溶液中腌制36小时,获得所需李子蜜饯;
(4)先将计量好的步骤(3)中的李子蜜饯倒入混合机中搅拌混合5min-10min,再把计量好的步骤(2)中处理好的外包裹物均匀洒在李子蜜饯表面,混合搅拌至外包裹物均匀地包裹在李子蜜饯的表面,获得食品;
(5)把包装袋,步骤(4)所得食品在强度为30W的紫外线下照射30分钟,消毒杀菌,然后及时包装,入库。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510983222.4A CN105558244A (zh) | 2015-12-24 | 2015-12-24 | 一种辅助降血脂降血糖并提高免疫力的食品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510983222.4A CN105558244A (zh) | 2015-12-24 | 2015-12-24 | 一种辅助降血脂降血糖并提高免疫力的食品及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105558244A true CN105558244A (zh) | 2016-05-11 |
Family
ID=55869364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510983222.4A Pending CN105558244A (zh) | 2015-12-24 | 2015-12-24 | 一种辅助降血脂降血糖并提高免疫力的食品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105558244A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108260812A (zh) * | 2016-12-30 | 2018-07-10 | 甘肃奇正实业集团有限公司 | 一种降血脂、降血糖、降血压、抗疲劳的保健食品及其加工方法 |
CN110915973A (zh) * | 2019-12-16 | 2020-03-27 | 北京园霖昌顺农业种植专业合作社 | 一种百合蜜饯及其制作方法 |
WO2021240553A1 (en) * | 2020-05-29 | 2021-12-02 | Laila Nutraceuticals | Synergistic herbal compositions for improving gut health |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101229213A (zh) * | 2007-01-24 | 2008-07-30 | 张宝毅 | 红景天组合物保健品 |
CN102670673A (zh) * | 2012-05-21 | 2012-09-19 | 信毅投资咨询(上海)有限公司 | 秋葵活性成分在制备防治代谢性疾病的药物中的应用 |
CN103432144A (zh) * | 2013-09-12 | 2013-12-11 | 山东大学 | 醉茄内酯类化合物在制备治疗或预防肿瘤、神经退行性疾病的药物或保健品中的应用 |
CN105166265A (zh) * | 2015-08-10 | 2015-12-23 | 普康林生物技术(北京)有限公司 | 一种改善代谢、调节生理机能的食品配方及其制备方法 |
-
2015
- 2015-12-24 CN CN201510983222.4A patent/CN105558244A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101229213A (zh) * | 2007-01-24 | 2008-07-30 | 张宝毅 | 红景天组合物保健品 |
CN102670673A (zh) * | 2012-05-21 | 2012-09-19 | 信毅投资咨询(上海)有限公司 | 秋葵活性成分在制备防治代谢性疾病的药物中的应用 |
CN103432144A (zh) * | 2013-09-12 | 2013-12-11 | 山东大学 | 醉茄内酯类化合物在制备治疗或预防肿瘤、神经退行性疾病的药物或保健品中的应用 |
CN105166265A (zh) * | 2015-08-10 | 2015-12-23 | 普康林生物技术(北京)有限公司 | 一种改善代谢、调节生理机能的食品配方及其制备方法 |
Non-Patent Citations (4)
Title |
---|
张立: "《猴头菇与胃健康》", 30 November 2014, 中国医药科技出版社 * |
李西林等: "《名贵中药材鉴别》", 31 October 2013, 上海科学技术出版社 * |
郭力等: "《中药化学》", 31 August 2015, 中国医药科技出版社 * |
马方: "《"三高"健康食疗图典》", 31 January 2011, 中国人口出版社 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108260812A (zh) * | 2016-12-30 | 2018-07-10 | 甘肃奇正实业集团有限公司 | 一种降血脂、降血糖、降血压、抗疲劳的保健食品及其加工方法 |
CN110915973A (zh) * | 2019-12-16 | 2020-03-27 | 北京园霖昌顺农业种植专业合作社 | 一种百合蜜饯及其制作方法 |
WO2021240553A1 (en) * | 2020-05-29 | 2021-12-02 | Laila Nutraceuticals | Synergistic herbal compositions for improving gut health |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102406860B (zh) | 预防和治疗糖尿病的组合物、其制备方法及应用 | |
KR101809172B1 (ko) | 뮤신이 없는 배지에서 배양한 아커만시아 뮤시니필라 균주 또는 이의 배양액을 유효성분으로 함유하는 대사성 질환의 예방, 개선 또는 치료용 조성물 | |
WO2011077800A1 (ja) | 高脂血症改善剤、並びに、貧血改善組成物、尿酸値低下組成物及び飲食品 | |
CN107365680A (zh) | 一种利用名酒大曲制备的食醋/醋膏及其应用 | |
SG176070A1 (en) | Lycopene and resveratrol dietary supplement | |
JP2012051940A (ja) | ビワ葉抽出物を含有する飲食品及び医薬品 | |
CN101766274B (zh) | 含竹叶黄酮的抗氧化功能食品组合物 | |
KR20150055876A (ko) | 체지방 감소 또는 체중 감소를 위한 조성물 | |
CN105232525A (zh) | 一种降血脂药物组合物及其应用 | |
CN105558244A (zh) | 一种辅助降血脂降血糖并提高免疫力的食品及其制备方法 | |
KR101672274B1 (ko) | 자화지정 추출물 또는 자화지정, 도인, 계지, 및 감초 복합 추출물을 포함하는 지질 관련 심혈관 질환 및 비만의 예방 또는 치료용 조성물 | |
CN102216318B (zh) | 抗氧化剂 | |
CN109123648A (zh) | 用于减轻癌症放化疗毒副作用的组合物及其制备方法 | |
CN109123351A (zh) | 一种具有高血糖人群代餐调节功能的特医食品及制备方法 | |
CN1927223A (zh) | 减肥养颜胶囊 | |
KR20110105627A (ko) | 누에 체액을 함유하는 항비만 조성물 | |
KR101160088B1 (ko) | 알코올성 지방간과 고지혈증 억제 및 숙취 억제 조성물 | |
CN108420890B (zh) | 一种具有降血脂作用的组合物及其制备方法 | |
CN101208351A (zh) | 用于治疗非自体免疫性2型糖尿病和/或x综合征的化合物 | |
CN105101817B (zh) | 可食用组合物及其制备方法和包含该组合物的食品 | |
JP5981088B2 (ja) | エネルギー消費促進剤 | |
Mathanghi | Nutraceutical properties of great millet-Sorghum vulgare | |
CN109364202B (zh) | 一种组合物及其制备方法和应用 | |
KR20070044198A (ko) | 푸마르산 및 푸마르산 유도체를 유효성분으로 함유하는대사증후군 치료제 | |
US20220062312A1 (en) | Oral composition comprising b-escin and the use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160511 |
|
RJ01 | Rejection of invention patent application after publication |